Ren茅 St-Arnaud
Professor
Ph.D
Glorieux Professor of Pediatric Musculoskeletal Research
Molecular mechanisms of Parathyroid Hormone osteoanabolic effects;
Osteoanabolic drug development.
Metabolic bone diseases
My integrated research program is aimed at identifying, characterizing, and validating targets for pharmacological intervention and development of rational, effective novel therapeutics for bone regenerative medicine. We use an integrated approach with biochemistry, molecular / cell biology, mouse molecular genetics and preclinical science to cover the full bench-to-bedside spectrum: target identification and characterization, high-throughput screening of small molecules for drug development, and validation of lead compounds.
Hariri, H., W.N. Addison, and R. St-Arnaud. 2021. Ubiquitin specific peptidase Usp53 regulates osteoblast versus adipocyte lineage commitment. Sci. Rep. 11: 8418.
Hariri, H., M. Pellicelli, and R. St-Arnaud. 2020. Nfil3, a target of the NACA transcriptional coregulator, affects osteoblast and osteocyte gene expression differentially. Bone 141: 115624.
Addison, W.N., M. Pellicelli, and R. St-Arnaud. 2019. Dephosphorylation of the transcriptional cofactor NACA by the PP1A phosphatase enhances cJUN transcriptional activity and osteoblast differentiation. J. Biol. Chem. 294: 8184-8196.
Martineau, C., R.P. Naja, A. Husseini, B. Hamade, M. Kaufmann, O. Akhouayri, A. Arabian, G. Jones, and R. St-Arnaud. 2018. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. J. Clin. Invest. 128: 3546-3557.
Pellicelli, M., H. Hariri, J.A. Miller, and R. St-Arnaud. 2018. Lrp6 is a target of the PTH-activated 蓱NAC transcriptional coregulator. Biochim. Biophys. Acta 1861: 61-71.